Levodopa/Carbidopa

左旋多巴/卡比多巴

Report date: 2026/04/03 20:03:44

Base Information

Drug NameLevodopa/Carbidopa
Drug Alias NameLevodopa and Carbidopa左旋多巴卡比多巴卡比多巴左旋多巴Carbidopa and Levodopa卡左双多巴 +[40] 
ClassificationSmall molecules
Mechanisms of ActionDOPA decarboxylase inhibitorsDopamine receptors agonists
TargetsAromatic-L-amino-acid decarboxylaseDopamine receptors
Therapy Area/IndicationsCognition DisordersDepressive Disorder, Treatment-ResistantDepressive Disorder, Major +[19] 
Global Approved IndicationsParkinson Disease, PostencephaliticParkinson Disease, SecondaryParkinson Disease
Approved Indications in ChinaParkinson Disease
Original Approved Country/TerritoryUnited States
Original Approved Date1975/05/02
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsYes LevodopaCarbidopa
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesOrganonAmneal Pharmaceuticals IncSynagile Co +[18] 
Inactive CompaniesAmnealJaeb Center For Health Research IncUcb Pharma +[11] 
Active IndicationsCognition DisordersDepressive Disorder, Treatment-ResistantDepressive Disorder, Major +[12] 
Inactive IndicationsCocaine-Related DisordersDiabetes MellitusAlbinism, Oculocutaneous +[7] 

Other Information

ATC CodeN04BA02
Related LinksWikipediaKEGG